Ivabradine Viatris (Ivabradine Oxalate)

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, the pacemaker of the heart. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, resulting in a reduced heart rate without affecting the strength of cardiac contraction.

The dosage of Ivabradine Viatris is determined by the prescribing clinician based on the individual’s clinical condition, heart‑rate response, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for ivabradine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Ivabradine Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and have broader cardiovascular effects, which may be advantageous or limiting depending on the patient’s comorbidities.

Ivabradine Viatris tablets should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency.

Ivabradine Viatris is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Dosing times are typically aligned with the patient’s daily routine, and the medication should be taken consistently each day.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and rare visual disturbances that may be persistent. Patients should be monitored for these events, especially when initiating therapy or when combined with other heart‑rate‑lowering agents.

Ivabradine Viatris is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, second‑ or third‑degree atrioventricular block, uncontrolled hypotension, or in those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine or any excipients.